World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD

Imagem de Miniatura
Arquivos
art_BANDELOW_World_Federation_of_Societies_of_Biological_Psychiatry_WFSBP_2023.PDF (5.23 MB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
BANDELOW, Borwin
ALLGULANDER, Christer
BALDWIN, David S.
DENYS, Damiaan
DILBAZ, Nesrin
DOMSCHKE, Katharina
HOLLANDER, Eric
KASPER, Siegfried
MOELLER, Hans-Juergen
Citação
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v.24, n.2, p.118-134, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim: This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders which was published in 2002 and revised in 2008. Method: A consensus panel of 34 international experts representing 22 countries developed recommendations based on efficacy and acceptability of the treatments. In this version, not only medications but also psychotherapies and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medication treatments. Result: The present paper (Part II) contains recommendations based on published randomised controlled trials (RCTs) for the treatment of OCD (n = 291) and PTSD (n = 234) in children, adolescents, and adults. The accompanying paper (Part I) contains the recommendations for the treatment of anxiety disorders. For OCD, first-line treatments are selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioural therapy (CBT). Internet-CBT was also superior to active controls. Several second-line medications are available, including clomipramine. For treatment-resistant cases, several options are available, including augmentation of SSRI treatment with antipsychotics and other drugs. Other non-pharmacological treatments, including repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS) and others were also evaluated. For PTSD, SSRIs and the SNRI venlafaxine are first-line treatments. CBT is the psychotherapy modality with the best body of evidence. For treatment-unresponsive patients, augmentation of SSRI treatment with antipsychotics may be an option. Conclusion: OCD and PTSD can be effectively treated with CBT and medications.
Palavras-chave
Obsessive-compulsive disorder, posttraumatic stress disorder, treatment, children, guideline
URI
https://observatorio.fm.usp.br/handle/OPI/53063
Referências
  1. American Psychiatric Association [APA], 2013, DIAGNOSTIC STAT MANU
  2. American Psychological Association, 2017, CLIN PRACT GUID TREA
  3. Bandelow Borwin, 2017, World J Biol Psychiatry, V18, P162, DOI 10.1080/15622975.2016.1190867
  4. Bandelow B, 2016, WORLD J BIOL PSYCHIA, V17, P321, DOI 10.1080/15622975.2016.1181783
  5. Bandelow B, 2015, INT CLIN PSYCHOPHARM, V30, P183, DOI 10.1097/YIC.0000000000000078
  6. Bandelow Borwin, 2002, World J Biol Psychiatry, V3, P171, DOI 10.3109/15622970209150621
  7. Bandelow B, 2008, WORLD J BIOL PSYCHIA, V9, P248, DOI 10.1080/15622970802465807
  8. Bertolini F, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013443.pub2
  9. Bisson JI, 2019, J TRAUMA STRESS, V32, P475, DOI 10.1002/jts.22421
  10. Bloch MH, 2010, MOL PSYCHIATR, V15, P850, DOI 10.1038/mp.2009.50
  11. Boudewyns PA, 1996, CLIN PSYCHOL PSYCHOT, V3, P185, DOI 10.1002/(SICI)1099-0879(199609)3:3<185::AID-CPP101>3.0.CO;2-0
  12. Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P81
  13. Cohen H, 2004, AM J PSYCHIAT, V161, P515, DOI 10.1176/appi.ajp.161.3.515
  14. Cougle JR, 2009, BEHAV RES THER, V47, P1012, DOI 10.1016/j.brat.2009.07.014
  15. Dell'Osso B, 2008, J PSYCHOPHARMACOL, V22, P210, DOI 10.1177/0269881107079865
  16. Denys D, 2003, J CLIN PSYCHOPHARM, V23, P568, DOI 10.1097/01.jcp.0000095342.32154.54
  17. Denys D, 2006, PSYCHIAT CLIN N AM, V29, P553, DOI 10.1016/j.psc.2006.02.013
  18. Devilly GJ, 1998, BEHAV THER, V29, P435, DOI 10.1016/S0005-7894(98)80042-7
  19. Dos Santos-Ribeiro Samara, 2018, Prim Care Companion CNS Disord, V20, DOI 10.4088/PCC.18r02342
  20. Dougherty DD, 2009, INT CLIN PSYCHOPHARM, V24, P306, DOI 10.1097/YIC.0b013e32833119d8
  21. Fineberg NA, 2007, EUR NEUROPSYCHOPHARM, V17, P430, DOI 10.1016/j.euroneuro.2006.11.005
  22. Fontenelle LF, 2015, J CLIN PSYCHIAT, V76, P949, DOI 10.4088/JCP.14r09129
  23. GREIST JH, 1995, INT CLIN PSYCHOPHARM, V10, P57, DOI 10.1097/00004850-199506000-00001
  24. Hageman SB, 2021, ACTA PSYCHIAT SCAND, V143, P307, DOI 10.1111/acps.13276
  25. HEWLETT WA, 1992, J CLIN PSYCHOPHARM, V12, P420
  26. Hollander E, 2003, J CLIN PSYCHIAT, V64, P1113, DOI 10.4088/JCP.v64n0919
  27. Hoppen LM, 2021, BMC PSYCHIATRY, V21, DOI 10.1186/s12888-021-03272-5
  28. KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
  29. King DW, 1996, J CONSULT CLIN PSYCH, V64, P520, DOI 10.1037/0022-006X.64.3.520
  30. Koenen KC, 2006, ANN NY ACAD SCI, V1071, P255, DOI 10.1196/annals.1364.020
  31. Langevin JP, 2016, BIOL PSYCHIAT, V79, pE82, DOI 10.1016/j.biopsych.2015.09.003
  32. Lewis C, 2020, EUR J PSYCHOTRAUMATO, V11, DOI 10.1080/20008198.2020.1729633
  33. Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231
  34. Miguel EC, 2019, MOL PSYCHIATR, V24, P218, DOI 10.1038/s41380-018-0054-0
  35. Montgomery S A, 1993, Eur Neuropsychopharmacol, V3, P143, DOI 10.1016/0924-977X(93)90266-O
  36. Montgomery SA, 2001, INT CLIN PSYCHOPHARM, V16, P75, DOI 10.1097/00004850-200103000-00002
  37. Ninan PT, 2006, J CLIN PSYCHIAT, V67, P15, DOI 10.4088/JCP.v67n0103
  38. Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183
  39. Pampaloni I, 2010, J PSYCHOPHARMACOL, V24, P1439, DOI 10.1177/0269881109104850
  40. Pereyra MO, 2021, B AM MUS NAT HIST, P1, DOI 10.1017/s0007485321000067
  41. Perkonigg A, 2000, ACTA PSYCHIAT SCAND, V101, P46, DOI 10.1034/j.1600-0447.2000.101001046.x
  42. Martinho FP, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19r12821
  43. Rabinowitz I, 2008, INT CLIN PSYCHOPHARM, V23, P49, DOI 10.1097/YIC.0b013e3282f0f0c5
  44. Rasmussen S, 1997, INT CLIN PSYCHOPHARM, V12, P309, DOI 10.1097/00004850-199711000-00003
  45. Rehn S, 2018, PSYCHIAT QUART, V89, P645, DOI 10.1007/s11126-018-9566-7
  46. Reid JE, 2021, COMPR PSYCHIAT, V106, DOI 10.1016/j.comppsych.2021.152223
  47. Roberts NP, 2019, EUR J PSYCHOTRAUMATO, V10, DOI 10.1080/20008198.2019.1695486
  48. Romano S, 2001, J CLIN PSYCHOPHARM, V21, P46, DOI 10.1097/00004714-200102000-00009
  49. Ruck C., 2006, THESIS
  50. Rufer M, 2005, EUR ARCH PSY CLIN N, V255, P121, DOI 10.1007/s00406-004-0544-8
  51. Shim GS, 2008, J CLIN PSYCHOPHARM, V28, P108, DOI 10.1097/JCP.0b013e318160d5f7
  52. Skapinakis P, 2016, LANCET PSYCHIAT, V3, P730, DOI 10.1016/S2215-0366(16)30069-4
  53. Stein DJ, 2007, CURR MED RES OPIN, V23, P701, DOI 10.1185/030079907X178838
  54. TOLLEFSON GD, 1994, ARCH GEN PSYCHIAT, V51, P559
  55. Uhre CF, 2020, J AM ACAD CHILD PSY, V59, P64, DOI 10.1016/j.jaac.2019.08.480
  56. van Emmerik AAP, 2002, LANCET, V360, P766, DOI 10.1016/S0140-6736(02)09897-5
  57. van Grootheest DS, 2005, TWIN RES HUM GENET, V8, P450, DOI 10.1375/183242705774310060
  58. van Wingen G, 2022, MOL PSYCHIATR, V27, P1276, DOI 10.1038/s41380-021-01411-8
  59. World Health Organization, 2018, INT STAT CLASS DIS R
  60. World Health Organization, 1993, ICD 10 CLASS MENT BE
  61. Wu H, 2021, MOL PSYCHIATR, V26, P60, DOI 10.1038/s41380-020-00933-x
  62. Yaryura-Tobias J A, 2000, World J Biol Psychiatry, V1, P197, DOI 10.3109/15622970009150592
  63. Zitterl W, 1999, WIEN KLIN WOCHENSCHR, V111, P439

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23